top of page

The PBM Conflict Checklist Every Plan Sponsor Should Run

Oct 27
5 min read

A recent ruling did not decide whether a PBM arrangement was imprudent. It decided that participants can put the question to a court. That is reason enough to ask yourself first.

On March 9, 2026, the U.S. District Court for the Southern District of New York issued a notable ruling in Stern v. JPMorgan Chase and Co. (No. 1:25-cv-02097). The decision is widely described as letting an ERISA PBM case proceed, but the precise holding matters: the court allowed the participants' prohibited-transaction claim, tied to JPMorgan's contracting with CVS Caremark as the plan's PBM, to move forward, while dismissing the breach-of-fiduciary-duty claims. The case is far from decided. What the ruling establishes is narrower and, for plan sponsors, more useful: participants can get a court to examine a PBM arrangement for conflicts.

That is the takeaway worth acting on. Not the headline number, not the merits, which remain contested and unproven, but the fact that PBM conflicts are now squarely litigable, and that the conditions plaintiffs point to are conditions a sponsor can check for in advance. Below is a checklist drawn from the structural concerns these cases raise.

Mar 9, 2026

Court let the prohibited-transaction claim proceed in Stern v. JPMorgan

1

Surviving claim type: prohibited transaction (duty claims were dismissed)

6

Conflict checks every plan sponsor can run now

What the Stern Ruling Actually Held

As NFP's analysis described, the court found that participants plausibly alleged prohibited transactions arising from JPMorgan's PBM contracting and related payments, allowing that portion of the case to proceed; the separate fiduciary breach allegations were dismissed. The plaintiffs' allegations include opaque pricing and compensation, such as retained rebates and spread pricing, and a formulary that allegedly steered toward higher-cost drugs over lower-cost alternatives. The defendants dispute the claims, and no wrongdoing has been established.

For a self-funded sponsor, the legal nuance is less important than the operational lesson: the features the plaintiffs pointed to are visible, in advance, in a PBM contract and its claims data. You do not need a lawsuit to find them. You need to look.

The ruling did not decide whether the PBM arrangement was imprudent. It decided that participants can ask a court. That alone is reason to ask the question first yourself.

The PBM Conflict Checklist

  • 1. Vertical integration. Is your PBM affiliated with a pharmacy, a drug manufacturer, or a rebate aggregator? Affiliation is not wrongdoing, but it is a conflict to be identified and monitored, not ignored.

  • 2. Formulary favoritism. Does the formulary steer to higher-cost, affiliate-manufactured drugs when lower-cost equivalents exist? Compare your formulary's preferred products to available alternatives.

  • 3. Spread pricing. Is there a gap between what the PBM charges the plan and what it pays the pharmacy? Spread is the classic opaque-compensation conflict.

  • 4. Rebate retention. What share of manufacturer rebates does the plan actually receive? Retained rebates are compensation you may not see in the headline fee.

  • 5. Compensation transparency. Can you obtain a full accounting of the PBM's direct and indirect compensation, as ERISA Section 408(b)(2) contemplates? If not, that gap is itself the issue.

  • 6. Independent verification. Has anyone outside the PBM examined the actual pharmacy claims, not just the PBM's reports, to confirm pricing and formulary behavior?

Why Running the Checklist Is Itself Prudence

The fiduciary lesson of the PBM litigation wave, which also includes cases against other large employers, is not that any particular sponsor did wrong. It is that selecting and monitoring a PBM is a fiduciary act, and that the conditions plaintiffs allege are checkable conditions. A sponsor who has run this checklist, documented the results, and acted on what it found has a fiduciary record. A sponsor who has not is relying on the PBM's own representations, exactly the posture these cases put on trial. Related: CAA 2026 and the DOL's Expanded Enforcement.

Run the Checklist on Your Own Claims, First

ClaimInformatics independently examines the pharmacy and medical claims behind your PBM's reports, surfacing conflicts, spreads, and formulary patterns, so you find them before a plaintiff does. Conflict-free, by design.

Schedule a confidential FOCUS™ assessment: claiminformatics.com/contact

Frequently Asked Questions

What did the court decide in Stern v. JPMorgan?

On March 9, 2026, the court allowed the participants' prohibited-transaction claim, tied to contracting with CVS Caremark as the plan's PBM, to proceed, while dismissing the breach-of-fiduciary-duty claims. The case is ongoing, the allegations are unproven, and the defendants dispute them.

Does the ruling mean JPMorgan did something wrong?

No. The court did not rule on the merits. It allowed one category of claim to survive dismissal, meaning participants may pursue it. The underlying allegations remain contested and unproven.

What is the practical takeaway for plan sponsors?

PBM conflicts are now squarely litigable, and the conditions plaintiffs point to, vertical integration, formulary favoritism, spread pricing, rebate retention, and opaque compensation, are ones a sponsor can check for in advance using a structured checklist.

Is it a problem if our PBM is vertically integrated?

Affiliation with a pharmacy, manufacturer, or rebate aggregator isn't wrongdoing in itself, but it is a conflict a prudent fiduciary should identify, monitor, and document rather than overlook. The checklist helps surface where affiliation may be affecting plan cost.

How does independent verification fit in?

The checklist's conditions live in the PBM contract and the actual pharmacy claims. Independent review of those claims, rather than the PBM's own reports, lets a sponsor confirm pricing, spread, and formulary behavior and create a defensible record of having looked.

The Bottom Line

Stern v. JPMorgan did not establish that any PBM arrangement was imprudent; it established that participants can ask a court to decide. For self-funded sponsors, that is reason enough to ask the question first, on their own terms. The conflicts these cases turn on are visible in advance, in the contract and the claims data. Running the checklist and documenting it is how a fiduciary turns a litigation trend into a defensible process.

Related Resources from ClaimInformatics

Of the six checks, which has your plan never actually run on its PBM? Share the gap in the comments.

Verified Sources

Source

Reference

Link

Georgetown Health Care Litigation Tracker

Stern v. JPMorgan Chase and Co., No. 1:25-cv-02097 (S.D.N.Y.)

NFP

ERISA Lawsuit on PBM Practices Moves Forward Against JPMorgan (Stern, Mar. 9, 2026 ruling)

Cornell LII

ERISA §408(b)(2) reasonable compensation (29 U.S.C. §1108)

Cornell LII

ERISA §406 prohibited transactions (29 U.S.C. §1106)

Cornell LII

ERISA §404 fiduciary duties (29 U.S.C. §1104)

This content is provided for fiduciary decision-making purposes and does not constitute legal advice. Stern v. JPMorgan is pending; all allegations are allegations only, are contested by the defendants, and no wrongdoing has been established.

Comments


bottom of page